Phaco technology platform

Article

The CENTURION Vision System sets a new standard of performance in cataract surgery by combining multiple, intelligent technologies and key features to provide surgeons control and improved efficiency during the cataract phaco procedure.

The CENTURION Vision System

The Only Intelligent Phacoemulsification Technology Designed to Optimize Cataract Surgery

Technology Overview and Unique Features
The CENTURION Vision System sets a new standard of performance in cataract surgery by combining multiple, intelligent technologies and key features to provide surgeons control and improved efficiency during the cataract phaco procedure.

The CENTURION Vision System is the only intelligent phaco technology that optimizes every moment of the cataract procedure. The new system automatically and continuously adapts to changing conditions within the eye, providing more consistent IOP (Intraocular Pressure) and greater anterior chamber stability during each step of the surgery. The CENTURION® Vision System places optimized energy technology at the surgeon's fingertips through enhanced fluidic management and surgical precision.1

Intelligent Technologies
Active Fluidics Technology is an automated system that optimizes anterior chamber stability by allowing surgeons to proactively set and maintain target IOP within the eye during the cataract procedure.1 This provides enhanced IOP control during the procedure in comparison to gravity fluidics and fixed pressure irrigation; reduces surges due to occlusion breaks; maintains a consistent IOP; and eliminates the need to manually adjust fluid pressure.

Balanced Energy Technology enhances phaco efficiency through proven OZil Intelligent Phaco and the INTREPID Balanced Tip probe. This increases efficiency and control, while reducing energy levels and accommodating surgeon settings for aspiration and vacuum by keeping the fragmented lens material at the shearing plane for emulsification.2,3

Applied Integration allows the CENTURION Vision System to be used seamlessly with multiple cataract surgical technologies, such as the LuxORTM Q-VUE surgical microscope platforms and the LenSX Laser from Alcon, to create a comprehensive cataract surgery suite designed to minimize variability at every step of the procedure.

The CENTURION Vision System also offers surgeons an improved ergonomic design, wireless footswitch and intuitive touch-screen display.

For more information about the CENTURION Vision system, please visit

www.centurionvisionsystem.com

References


1. Data on File, Alcon Laboratories.
2. A.R. Vasaveda

et al.

, Ophthalmic Surg. Lasers Imaging, 2010;

41

(1):109–114.
3. R.J. Cionni, A.S. Crandall and D. Felsted,

J. Cataract Refract. Surg.

, 2011;

37

(10):1795–1790.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.